Sign in
Taking peoplePhase 3

The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

Key facts

Who runs it
Oupushifang Pharmaceutical Technology Co., Ltd.
Where
China25 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
606 people, planned
Started
15 Jun 2024
Expected to end
31 Dec 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Atropine sulfate eye drops 0.01%
  • Atropine sulfate eye drops 0.02%
  • Placebo eye drops
Record updated
24 December 2024

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • The legal guardian of the subject voluntarily signed the written informed consent, and the subject over 8 years is required to sign the written informed consent voluntarily
  • Patients with myopia aged 6 to 12 years, including cut-offs
  • The equivalent spherical refraction ranges from -1.00 D to -4.00 D (automatic optometry under a cycloplegia condition) in both myopia eyes at inclusion screening
  • The astigmatism of both eyes was ≤ 1.50 D under a cycloplegia condition at inclusion screening
  • The antimetropia (measured by equivalent spherical refraction) is < 2.00 D at inclusion screening
  • Able to comply with study requirements, attend all study visits (including telephone visits), and be willing to receive random grouping of atropine treatment or placebo

Who cannot take part

  • Use of low-concentration (0.05% and below) atropine sulfate eye drops (including various in-hospital preparations, except for test drugs) and orthokeratology lenses (OK lenses) within 6 months before the screening
  • Use of other myopia control methods such as instruments (multifocal glasses, progressive multifocal glasses, etc.), medications (the use of cycloplegic agents for examinations such as optometry is allowed), and others (including traditional Chinese medicine, auricular acupuncture, massage, accommodative flippers, red light therapy instrument, etc.) within 3 months before screening
  • Those who have participated in other clinical trials and received drug or medical device interventions within 3 months before screening
  • Systemic or topical use of drugs that affect the efficacy evaluation, such as anticholinergics: atropine, pirenzepine, etc., and cholinomimetics: pilocarpine, etc. within 1 week before screening
  • Surgical intervention (ocular or systemic) within 6 months before screening, or planned surgery during the study
  • Need for ocular use or systemic oral corticosteroids during the study. Intranasal, inhaled, topical cutaneous, intra-articular, perianal steroids, and short-term oral steroids (i.e., continuous use for < 2 weeks)
  • Allergic to this product or its excipients
  • Suffering from eye diseases that may affect vision (e.g. lens diseases such as cataracts, glaucoma, fundus macular disease, keratopathy, uveitis, retinal detachment, severe vitreous opacity, etc., manifest strabismus, nystagmus, ocular acute inflammatory disease), history of recurrent chronic ocular inflammation, or any other ocular pathology (e.g., angular stenosis, shallow anterior chamber)
  • Combined with severe immune system disease, central nervous system disease, Down syndrome, asthma, cardiopulmonary insufficiency, liver and kidney dysfunction, etc
  • Heart rate sustained (more than 10 minutes) greater than 120 beats/min at screening (after 10 minutes of rest if the ECG shows a heart rate greater than 120 beats per minute, the ECG should be retested 10 minutes later. If the retest result below 120 beats/min, the screening is successful; If the retest result is still >120 beats/min, screening failed)
  • Other conditions that are considered unsuitable by the investigator
  • Intraocular pressure of either eye is > 21 mmHg or <10 mmHg at screening

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 12 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The clinical trial aims to test the effectiveness and safety of two low-dose atropine sulfate eye drops for delaying myopia progression in children and adolescents.

Read full original descriptionShow less

Primary Objective: evaluate the effectiveness of 0.01% and 0.02% atropine sulfate eye drops for 96 weeks compared to placebo in delaying myopia progression in children and adolescents. Secondary Objective: evaluate the safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) in delaying myopia progression in children and adolescents.

Exploratory Objective:

1. the efficacy and safety of two low-concentration atropine sulfate eye drops (0.01%/0.02%) for 144 weeks. 2. evaluate the rebound effect of two low-concentration atropine sulfate eye drops (0.01%/0.02%) after discontinuation.

The 3 groups in the trial

  • Experimental group (0.01% atropine sulfate eye drops)Existing treatment, for comparison

    1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

    Treatment: Atropine sulfate eye drops 0.01%

  • Experimental group (0.02% atropine sulfate eye drops)Existing treatment, for comparison

    1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

    Treatment: Atropine sulfate eye drops 0.02%

  • Control group (placebo eye drops)Placebo, for comparison

    1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.

    Treatment: Placebo eye drops

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Progression of Myopia in Children and Adolescents in a Randomized, Double-blind, Placebo Parallel-controlled, Multicenter, Phase III Clinical Trial
Criteria questions
Built from NCT06708156, who can take part
Record updated
24 December 2024